# EDGAR Filing Document

**Accession Number:** 0001298711
**File Stem:** 0001298711-23-000006
**Filing Date:** 2023-1
**Character Count:** 9800
**Document Hash:** 0cd341ed9a9d35f238bf7398be712790
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001298711-23-000006.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001298711-23-000006

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230117

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Krishnan Suma
- **CENTRAL INDEX KEY:** 0001298711

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38210
- **FILM NUMBER:** 23538390

**MAIL ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Krystal Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001711279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 821080209
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
- **BUSINESS PHONE:** (412) 586-5830

**MAIL ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Krishnan Suma<br><sub>(Last) (First) (Middle)</sub><br>C/O KRYSTAL BIOTECH, INC.<br>2100 WHARTON STREET, SUITE 701<br><sub>(Street)</sub><br>PITTSBURGH, PA 15203<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President, R&D_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Krystal Biotech, Inc. [ KRYS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-17 |  | S<sup>(1)</sup> |  | 20617 | D | 80.7019<sup>(2)</sup> | 1681646 | D |  |
| Common Stock | 2023-01-17 |  | S<sup>(1)</sup> |  | 1186 | D | 81.4067<sup>(3)</sup> | 1680460 | D |  |
| Common Stock | 2023-01-17 |  | S<sup>(1)</sup> |  | 345 | D | 82.7153<sup>(4)</sup> | 1680115 | D |  |
| Common Stock | 2023-01-17 |  | S<sup>(5)</sup> |  | 20617<sup>(6)</sup> | D | 80.7019<sup>(2)</sup> | 1743071 | I | By Spouse<sup>(7)</sup> |
| Common Stock | 2023-01-17 |  | S<sup>(5)</sup> |  | 1186<sup>(6)</sup> | D | 81.4062<sup>(3)</sup> | 1741885 | I | By Spouse<sup>(7)</sup> |
| Common Stock | 2023-01-17 |  | S<sup>(5)</sup> |  | 346<sup>(6)</sup> | D | 82.7144<sup>(4)</sup> | 1741539 | I | By Spouse<sup>(7)</sup> |
| Common Stock | 2023-01-18 |  | S<sup>(1)</sup> |  | 2048 | D | 80.7527<sup>(8)</sup> | 1678067 | D |  |
| Common Stock | 2023-01-18 |  | S<sup>(1)</sup> |  | 804 | D | 81.5592<sup>(9)</sup> | 1677263 | D |  |
| Common Stock | 2023-01-18 |  | S<sup>(5)</sup> |  | 2048<sup>(6)</sup> | D | 80.7531<sup>(8)</sup> | 1739491 | I | By Spouse<sup>(7)</sup> |
| Common Stock | 2023-01-18 |  | S<sup>(5)</sup> |  | 803<sup>(6)</sup> | D | 81.5592<sup>(9)</sup> | 1738688 | I | By Spouse<sup>(7)</sup> |
| Common Stock |  |  |  |  |  |  |  | 90000 | I | By SMK Trust |
| Common Stock |  |  |  |  |  |  |  | 50000 | I | By Krishnan Family Trust<sup>(10)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.

(2) The transaction was executed in multiple trades ranging from $80.1300 to $81.1000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

(3) The transaction was executed in multiple trades ranging from $81.1300 to $82.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

(4) The transaction was executed in multiple trades ranging from $82.3300 to $83.2500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

(5) The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.

(6) These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.

(7) Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

(8) The transaction was executed in multiple trades ranging from $80.3500 to $81.3300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

(9) The transaction was executed in multiple trades ranging from $81.3700 to $81.9200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

(10) Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.

**Signature:** /s/ Suma Krishnan  
**Date:** 2023-01-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**